Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ultralow Dose PAH Binary Mixture Study
NCT03631667Phase 1Completed
- Sponsor
- Oregon State University
- Start
- Oct 2018
- Primary completion
- Jan 2024
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial, sponsored by Oregon State University. Primary endpoints: Peak Plasma Concentration of 14C-BaP and Time at Highest Plasma Concentration of 14C-BaP. Started Oct 2018; status: completed.
Beyond the preview
Go deeper on NCT03631667.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03631667.